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Po
xMBACKGROUND Although most patients in the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine
Impact on Global Mortality and Morbidity in Heart Failure) trial had mild symptoms, there is a poor correlation between
reported functional limitation and prognosis in heart failure.
OBJECTIVES The aim of this study was to examine the spectrum of risk in PARADIGM-HF and the effect of LCZ696
across that spectrum.
METHODS This study analyzed rates of the primary composite outcome of cardiovascular death or heart failure hospitaliza-
tion, its components, and all-cause mortality using the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) and
EMPHASIS-HF (Eplerenone inMildPatientsHospitalizationandSurvivalStudy inHeartFailure) riskscores tocategorizepatients.
The authors determined whether risk, on the basis of these scores, modiﬁed the treatment effect of LCZ696.
RESULTS The complete MAGGIC risk score was available for 8,375 of the 8,399 patients in PARADIGM-HF. The median
MAGGIC score was 20 (IQR: 16 to 24). An increase of 1 point was associated with a 6% increased risk for the primary
endpoint (p < 0.001) and a 7% increased risk for cardiovascular death (p < 0.001). The beneﬁt of LCZ696 over enalapril
for the primary endpoint was similar across the spectrum of risk (p ¼ 0.159). Treating 100 patients for 2 years with
LCZ696 instead of enalapril led to 7 fewer patients in the highest quintile of risk experiencing primary outcomes,
compared with 3 in the lowest quintile. Analyses using the EMPHASIS-HF risk score gave similar ﬁndings.
CONCLUSIONS Although most PARADIGM-HF patients had mild symptoms, many were at high risk for adverse out-
comes and obtained a large absolute beneﬁt from LCZ696, compared with enalapril, over a relatively short treatment
period. LCZ696’s beneﬁt was consistent across the spectrum of risk. (PARADIGM-HF trial [Prospective Comparison of
ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure]; NCT01035255)
(J Am Coll Cardiol 2015;66:2059–71) © 2015 by the American College of Cardiology Foundation.m the *BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom; yDepartment of Cardiology,
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ABBR EV I A T I ON S
AND ACRONYMS
ACEI = angiotensin-converting
enzyme inhibitor
AF = atrial ﬁbrillation
ARB = angiotensin receptor
blocker
BMI = body mass index
BNP = B-type natriuretic
peptide
eGFR = estimated glomerular
ﬁltration rate
HF = heart failure
HFrEF = heart failure with
reduced ejection fraction
LVEF = left ventricular ejection
fraction
NYHA = New York Heart
Association
SBP = systolic blood pressure
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2060A lthough well-treated patients withheart failure (HF) may have fewsymptoms and little functional
limitation, many remain at substantial risk
for death and other adverse outcomes. This
is due in part to the limited correlation
between powerful prognostic variables, such
as left ventricular ejection fraction (LVEF),
and comorbidities, symptoms, and functional
capacity. The New York Heart Association
(NYHA) classiﬁcation encompasses a wide
and overlapping range of risks, as was
recently illustrated in EMPHASIS-HF (Eplere-
none in Mild Patients Hospitalization and
Survival Study in Heart Failure) (1). Although
all patients were in NYHA functional class II
at entry, when categorized into low-,
medium-, and high-risk groups using a pre-
dictive score, the rate of the primary endpoint
(cardiovascular death or HF hospitalization)ranged from 7.6 to 39.4 per 100 person-years in the
placebo-treated patients (the rate in the medium-risk
group was 19.0 per 100 person-years) (2).SEE PAGE 2072Most patients in the PARADIGM-HF (Prospective
Comparison of ARNI With ACEI to Determine Impact
on Global Mortality and Morbidity in Heart Failure)
trial also had mild symptoms (5% were in NYHA
functional class I and 70% in class II), although
24% and 0.7% were in NYHA functional classes III
and IV, respectively, at randomization (3). We
therefore calculated the baseline risk of patients in
PARADIGM-HF using the MAGGIC (Meta-Analysis
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received June 16, 2015; revised manuscript received August 19,which was derived and validated in patients with
a broad spectrum of symptoms and functional
limitations (4). We also analyzed risk using the
EMPHASIS-HF score in PARADIGM-HF patients in
NYHA functional classes I and II only (2). Addition-
ally, we examined the effect of the angiotensin re-
ceptor neprilysin inhibitor LCZ696 compared with
enalapril, according to baseline risk calculated using
these scores.
METHODS
The study design, patient characteristics, and key
results of the PARADIGM-HF trial have been
described in detail (3,5–7). The ethics committee of
each of the 1,043 participating institutions (in 47
countries) approved the protocol, and all patients
gave written, informed consent.
PATIENTS AND PROCEDURES
Patients had NYHA functional class II through IV
symptoms, LVEF #40% (changed to #35% by
amendment), and plasma B-type natriuretic peptide
(BNP) levels $150 pg/ml (or N-terminal pro-BNP
levels $600 pg/ml). Patients who had been hospital-
ized for HF within 12 months were eligible for
enrollment with lower natriuretic peptide concen-
trations (BNP $100 pg/ml or N-terminal pro-
BNP $400 pg/ml). Patients also were required to be
taking angiotensin-converting enzyme inhibitors
(ACEIs) or angiotensin receptor blockers (ARBs) in
doses equivalent to enalapril 10 mg/day for at least 4
weeks before screening, along with stable doses of
beta-blockers (unless contraindicated or not toler-
ated) and mineralocorticoid receptor antagonists, ifmaceutical Corporation, East Hanover, New Jersey;
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ular, Biomedical Research Unit, Glenﬁeld Hospital,
en’s Hospital, Boston, Massachusetts; zzInstitut de
ent of Molecular and Clinical Medicine, University
a and RHJ Department of Veterans Administration
linical Sciences, University of Texas Southwestern
by Novartis. All authors or their institutions have
. Jhund has consulted for Novartis. Dr. Packer has
ol, Janssen, Amgen, CardioMEMS, and Cardiorentis.
rtis for Prof. McMurray’s time spent as cochairman
the trial and LCZ696; and Prof. McMurray’s travel
. Dr. Solomon has received research support from
as consulted for Novartis, Merck, Relypsa, and St.
Novartis. Drs. Mosterd and Squire have received
sory boards. Dr. Swedberg has received honoraria
serving on executive and steering committees. Dr.
grants from Novartis and Cardiorentis. Drs. Mosterd
ctivities.
2015, accepted August 30, 2015.
J A C C V O L . 6 6 , N O . 1 9 , 2 0 1 5 Simpson et al.
N O V E M B E R 1 0 , 2 0 1 5 : 2 0 5 9 – 7 1 Effect of ARNI According to the MAGGIC Risk Score
2061indicated. The exclusion criteria were history of
intolerance of an ACEI or ARB, symptomatic hypo-
tension (or systolic blood pressure [SBP] <100 mm Hg
at screening or <95 mm Hg at randomization), esti-
mated glomerular ﬁltration rate (eGFR)<30ml/min/1.73m2
at screening or at randomization (or a decrease in eGFR
>25% [amended to 35%] between screening and
randomization), serum potassium concentration >5.2
mmol/l at screening (>5.4 mmol/l at randomization),
recent acute coronary syndrome, cardiovascular proce-
dure or surgery, anticipated cardiac transplantation, and
the presence of any other disease with a life
expectancy <5 years. On trial entry, existing treatment
with an ACEI or ARB was stopped, but other HF treat-
ments were continued. Patients started enalapril 10 mg
twice daily for 2 weeks, then took LCZ696 (both single
blind) for an additional 4 to 6 weeks, initially at 100 mg
twice daily, then 200 mg twice daily. Patients tolerating
both drugs at the target doses were randomly assigned
to double-blind treatment with either enalapril 10 mg
twice daily or LCZ696 200 mg twice daily (in a 1:1 ratio).
LCZ696 200 mg twice daily delivers the equivalent of
valsartan 160 mg twice daily and signiﬁcant and sus-
tained neprilysin inhibition.
STUDY OUTCOMES. The primary outcome was a
composite of death of cardiovascular causes or a ﬁrst
hospitalization for HF. Secondary outcomes were
time to death of any cause, change from baseline to
8 months in the clinical summary score on the Kansas
City Cardiomyopathy Questionnaire (on a scale of 0 to
100, with higher scores indicating fewer HF-related
symptoms and physical limitations), time to new-
onset atrial ﬁbrillation (AF), and time to ﬁrst occur-
rence of a decline in renal function. The focus of the
present analyses was on the primary composite
outcome, its components, and all-cause mortality.
RISK SCORES. The baseline risk for each patient in
PARADIGM-HF was calculated using the MAGGIC
score, the derivation and validation of which have
been published (4,8). Brieﬂy, a multivariate risk
model was built after examination of 31 candidate
variables in 39,372 patients enrolled in 30 clinical
trials and cohort studies. Thirteen independent pre-
dictors of all-cause mortality were identiﬁed: age
(per 10 years), male sex, body mass index (BMI) (per
1 kg/m2 increase up to 30 kg/m2), current smoking,
diabetes, SBP (per 10 mm Hg increase), NYHA func-
tional class, LVEF (per 5% increase up to 40%),
chronic obstructive pulmonary disease, HF duration
>18 months, creatinine (per 10 mmol/l up to 350 mmol/l),
ACEI or ARB use, and beta-blocker use (signiﬁcant
interactions between both LVEF and age and between
LVEF and SBP were also identiﬁed). A simple integerscore was derived. The maximum score is 57, and an
online risk calculator is available.
EMPHASIS-HF enrolled only patients with HF with
reduced ejection fraction (HFrEF) and NYHA func-
tional class II symptoms. The EMPHASIS-HF risk
score, developed for the primary composite outcome
of cardiovascular death or HF hospitalization (as well
as all-cause mortality), uses a similar approach to that
used in MAGGIC (2) and is the only risk score specif-
ically developed in patients with mild symptoms. The
risk model was validated in a subset of patients from
CHARM (Candesartan in Heart Failure: Assessment of
Reduction in Mortality and Morbidity Programme)
(2). More variables (including routine hematologic
and biochemical variables) were available in the
EMPHASIS-HF dataset than for the MAGGIC popula-
tion, and 10 were identiﬁed as strong independent
risk factors for the primary outcome, namely, age,
sex, SBP, eGFR, diabetes, BMI, hemoglobin, prior HF
hospitalization, prior myocardial infarction or coro-
nary artery bypass grafting, and heart rate. However,
this risk model does not take into account NYHA
functional class (all patients in EMPHASIS-HF were in
NYHA functional class II) or treatment (93% of pa-
tients were treated with ACEIs or ARBs and 87% with
beta-blockers). To calculate a patient’s risk score, for
each binary variable, 1 point was added. For contin-
uous variables, a binary categorization adequately
explained the variation in risk, and 1 point was added
for age $75 years, SBP <130 mm Hg, BMI <25 kg/m2,
and heart rate >80 beats/min. For eGFR and hemo-
globin, 3 level categorizations better explained vari-
ation in risk, and therefore 2 points were added for
eGFR <60 ml/min/1.73 m2 or hemoglobin <11 g/dl and
1 point for eGFR 60 to 69 ml/min/1.73 m2 or hemo-
globin 11 to 12.9 g/dl. The maximum possible score
was 12 (range: 0 to 12).
STATISTICAL ANALYSIS. Patients were divided into
5 quintiles of MAGGIC risk score (4 to 15, 16 to 18, 19 to
21, 22 to 25, and 26 to 40). The relationship between
MAGGIC risk score category and baseline character-
istics was examined using a trend test for continuous
variables. For normally distributed variables, this was
a regression test; for skewed variables, the Cuzick
nonparametric trend test was used. Categorical vari-
ables were tested using chi-square test. The primary
composite outcome, its components, and all-cause
mortality were analyzed for each category. The
effect of LCZ696 versus enalapril on each outcome
across the spectrum of risk was examined in a Cox
regression model. The interaction between risk and
treatment on the occurrence of the pre-speciﬁed
outcomes was tested in a logistic regression model
with an interaction term between risk and treatment.
FIGURE 1 Distribution of Risk Scores and Probability of Reaching
Primary Composite Endpoint
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Frequency Enalapril LCZ696
A
B
As shown by histogram, distribution of patients by (A) MAGGIC (Meta-Analysis Global
Group in Chronic Heart Failure) risk score (n ¼ 8,375) and (B) EMPHASIS (Eplerenone in
Mild Patients Hospitalization and Survival Study in Heart Failure) risk score (n ¼ 6,112) and
the association of each with reaching the primary composite endpoint of cardiovascular
death or heart failure hospitalization shown by treatment.
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2062The interaction between treatment and risk score was
conducted with the risk score as a continuous vari-
able. Pre-speciﬁed adverse events according to risk
score category were also examined.
The MAGGIC risk score assigns 1 point to patients
with a duration of HF of 18 months or longer. How-
ever, HF duration in PARADIGM-HF was recorded in
the categories 0 to 3 months, 3 to 6 months, 6 to
12 months, 1 to 2 years, 2 to 5 years, and >5 years. For
the main analysis, we added 1 point to a patient’s
score for HF duration $1 year and in a sensitivity
analysis (Online Tables 1 and 2, Online Figures 1
and 2) for patients with HF for $2 years. Sensi-
tivity analyses were also carried out for clinicaloutcomes related to MAGGIC risk score according
to presence or absence of AF and geographic
region (North America vs. the rest of the world) and
(Online Tables 3 to 10).
An identical approach was taken in the analysis of
the EMPHASIS-HF risk score, although it was applied
only to patients in NYHA functional class I or II.
Patients were split into 5 categories of approximately
equal size: those with scores of 0 to 3, 4, 5, 6, or 7 to
12 points.
All analyses were conducted using Stata version
12.1 (StataCorp LP, College Station, Texas) and SAS
version 9.4 (SAS Institute Inc., Cary, North Carolina).
A p value <0.05 was considered to indicate statistical
signiﬁcance.
RESULTS
Overall, 8,399 patients aged 18 to 96 years were
validly randomized, 8,375 of which had complete data
across all 13 variables required for MAGGIC risk score
calculation. The mean age was 64 years, 78% were
men, and 70% of participants were in NYHA func-
tional class II and 24% in class III. Figure 1A shows the
distribution of MAGGIC risk scores in PARADIGM-HF.
The median score was 20 points (IQR: 16 to 24 points;
range: 4 to 40 points). Table 1 shows the numbers and
proportions of patients in the different MAGGIC risk-
score categories analyzed.
Compared with patients with lower scores, those
with higher scores were older and more often male,
white, and enrolled in Western Europe and North
America (Table 1). Patients with higher risk scores also
had a lower mean SBP, LVEF, and BMI but higher
mean creatinine and natriuretic peptide levels and
were more likely to be in NYHA functional class III or
IV than I or II and to have worse Kansas City Cardio-
myopathy Questionnaire score, ischemic etiology
(and other evidence of coronary heart disease), and
additional comorbidities. With respect to background
treatment of HF, beta-blocker use was less, but
diuretic therapy, digoxin use, and device therapy
were greater in patients with high scores.
OUTCOMES. When examined as a continuous vari-
able, each 1-point increase in score was associated
with a 6% (95% conﬁdence interval: 5% to 7%)
higher risk for the primary composite outcome of
cardiovascular death or HF hospitalization (p < 0.001)
(Figure 1A).
The unadjusted incidence of the primary out-
come according to baseline risk category and ran-
domized treatment is shown in Table 2 and the
Central Illustration (as a rate per 100 patient-years of
TABLE 1 MAGGIC Risk Score: Baseline Characteristics and Treatment
Risk Score Category (Points)
p Value for Trend
4–15
(n ¼ 1,762)
16–18
(n ¼ 1,637)
19–21
(n ¼ 1,675)
22–25
(n ¼ 1,842)
26–40
(n ¼ 1,459)
Age, yrs 53.9  9.2 59.5  9.0 63.5  9.4 68.6  8.8 74.9  7.4 <0.0001
Female 492 (27.9) 381 (23.3) 358 (21.4) 368 (20.0) 230 (15.8) <0.0001
Race <0.0001
White 1,040 (59.0) 1,020 (62.3) 1,076 (64.2) 1,303 (70.7) 1,088 (74.6)
Black 139 (7.9) 104 (6.4) 77 (4.6) 56 (3.0) 50 (3.4)
Asian 366 (20.8) 332 (20.3) 327 (19.5) 305 (16.6) 175 (12.0)
Other 217 (12.3) 181 (11.1) 195 (11.6) 178 (9.7) 146 (10.0)
Region <0.0001
North America 84 (4.8) 91 (5.6) 106 (6.3) 155 (8.4) 164 (11.2)
Latin America 352 (20.0) 291 (17.8) 315 (18.8) 269 (14.6) 202 (13.8)
Western Europe and other 324 (18.4) 380 (23.2) 388 (23.2) 489 (26.5) 459 (31.5)
Central Europe 636 (36.1) 544 (33.2) 547 (32.7) 631 (34.3) 465 (31.9)
Asia-Paciﬁc 366 (20.8) 331 (20.2) 319 (19.0) 298 (16.2) 169 (11.6)
SBP, mm Hg 124.9  15.1 122.4  15.9 120.7  15.5 120.3  15.0 118.2  14.1 <0.0001
DBP, mm Hg 77.4  10.0 74.6  9.7 73.2  9.8 72.3  9.7 69.9  9.7 <0.0001
Heart rate, beats/min 73.6  12.2 72.4  11.9 72.3  12.4 71.7  11.9 71.6  11.7 <0.0001
BMI, kg/m2 30.3  6.0 28.9  5.4 27.8  5.3 27.4  5.3 26.5  4.6 <0.0001
Creatinine, mmol/l 86.8  18.9 92.5  21.0 97.7  23.7 104.0  26.6 117.8  29.8 <0.0001
eGFR, ml/min/1.73m2 78.9  20.9 72.7  18.1 68.2  18.6 62.6  17.0 54.4  16.4 <0.0001
Hemoglobin, g/l 141.9  15.6 141.1  15.7 140.1  16.2 137.4  16.1 136.0  15.7 <0.0001
BNP, pg/ml 209.6 (127.0–378.2) 277.6 (146.0–434.5) 256.2 (155.5–476.0) 275.1 (168.0–489.7) 317.5 (182.4–592.9) <0.0001
NT-proBNP, pg/ml 1,198 (724–2,220) 1,379 (785–2,580) 1,625 (890–3,136) 1,846 (1,066–3,719) 2,435 (1,254–4,998) <0.0001
Ischemic etiology 837 (47.5) 895 (54.7) 1,019 (60.8) 1,232 (66.9) 1,036 (71.0) <0.0001
Ejection fraction, % 32.0 (4.9) 29.7 (5.9) 29.2 (6.1) 28.7 (6.4) 27.7 (6.8) <0.0001
NYHA functional class <0.0001
I 141 (8.0) 95 (5.8) 72 (4.3) 62 (3.4) 18 (1.2)
II 1,514 (85.9) 1,311 (80.1) 1,242 (74.1) 1,154 (62.6) 689 (47.2)
III 107 (6.1) 224 (13.7) 352 (21.0) 609 (33.1) 725 (49.7)
IV 0 (0) 7 (0.4) 9 (0.5) 17 (0.9) 27 (1.9)
KCCQ score 84.4 (68.8–93.8) 82.8 (67.7–93.8) 81.3 (65.1–92.7) 78.1 (60.4–89.6) 72.9 (55.2–87.0) <0.0001
Medical history
Hypertension 1,205 (68.4) 1,119 (68.4) 1,174 (70.1) 1,333 (72.4) 1,094 (75.0) <0.0001
Diabetes 310 (17.6) 481 (29.4) 586 (35.0) 775 (42.1) 749 (51.3) <0.0001
Atrial ﬁbrillation 507 (28.8) 530 (32.4) 588 (35.1) 750 (40.7) 704 (48.3) <0.0001
Hospitalization for heart failure 1,130 (64.1) 995 (60.8) 1,024 (61.1) 1,158 (62.9) 953 (65.3) 0.0663
Myocardial infarction 574 (32.6) 652 (39.8) 738 (44.1) 904 (49.1) 754 (51.7) <0.0001
Stroke 101 (5.7) 115 (7.0) 153 (9.1) 163 (8.8) 193 (13.2) <0.0001
Coronary artery bypass surgery 163 (9.3) 217 (13.3) 244 (14.6) 328 (17.8) 346 (23.7) <0.0001
Percutaneous coronary intervention 299 (17.0) 334 (20.4) 372 (22.2) 457 (24.8) 335 (23.0) <0.0001
Treatment
Diuretic agent 1,365 (77.5) 1,287 (78.6) 1,310 (78.2) 1,493 (81.1) 1,265 (86.7) <0.0001
Digoxin 495 (28.1) 487 (29.7) 504 (30.1) 553 (30.0) 495 (33.9) 0.009
Beta-blocker 1,721 (97.7) 1,583 (96.7) 1,579 (94.3) 1,674 (90.9) 1,232 (84.4) <0.0001
Mineralocorticoid receptor antagonist 1,016 (57.7) 932 (56.9) 971 (58.0) 995 (54.0) 745 (51.1) 0.0002
Oral anticoagulant agent 469 (26.6) 522 (31.9) 549 (32.8) 608 (33.0) 529 (36.3) <0.0001
Antiplatelet agent 921 (52.3) 915 (55.9) 962 (57.4) 1,082 (58.7) 844 (57.8) 0.001
Lipid-lowering agent 901 (51.1) 891 (54.4) 963 (57.5) 1,099 (59.7) 866 (59.4) <0.0001
Implantable cardioverter-deﬁbrillator 151 (8.6) 221 (13.5) 244 (14.6) 324 (17.6) 299 (20.5) <0.0001
Cardiac resynchronization therapy 52 (3.0) 75 (4.6) 119 (7.1) 164 (8.9) 162 (11.1) <0.0001
Values are mean  SD, n (%), or median (interquartile range).
BMI ¼ body mass index; BNP ¼ B-type natriuretic peptide; DBP ¼ diastolic blood pressure; eGFR ¼ estimated glomerular ﬁltration rate; KCCQ ¼ Kansas City Cardiomyopathy Questionnaire; MAGGIC ¼
Meta-Analysis Global Group in Chronic Heart Failure; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; NYHA ¼ New York Heart Association; SBP ¼ systolic blood pressure.
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2064follow-up). The incidence of this endpoint in the
enalapril (control) group increased incrementally
with increasing score.
The effect of LCZ696 compared with enalapril
was consistent across the range of risk scores exam-
ined as a categorical variable (Table 2, Central
Illustration). As a result, the absolute treatment ef-
fect was greater in patients with higher risk scores.
For example, applying the overall proportional risk
reduction (20%) with LCZ696 (compared with ena-
lapril) in PARADIGM-HF to patients with risk scores of
26 to 40 points would lead to 8 fewer patients per 100
treated for 2 years experiencing events compared
with 4 in the category with 4 to 15 points.
The rates of both cardiovascular death and HF hos-
pitalization, individually, in the enalapril group
increased stepwise with increasing score (Table 2,
Central Illustration). When the score was examined
as a continuous variable, each 1-point increase in
score was associated with a 7% (95% conﬁdence
interval: 6% to 8%) higher risk for cardiovascular death
(p < 0.001).
The effect of LCZ696 compared with enalapril was
consistent across the spectrum of risk examined as
a categorical variable (Table 2, Central Illustration) or
continuous variable. The p values for the interac-
tion between risk score and treatment effect were
0.88 for cardiovascular death and 0.02 for HF
hospitalization.
The rate of death from any cause increased step-
wise with increasing risk category (Table 2, Central
Illustration). When examined as a continuous vari-
able, each 1-point increase in score was associated
with a 7% (95% conﬁdence interval: 6% to 8%) higher
risk for cardiovascular death (p < 0.001).
The effect of LCZ696 compared with enalapril was
consistent across the spectrum of risk examined as a
categorical variable (Table 2, Central Illustration) or
continuous variable (Figure 1A). The absolute treat-
ment effect was greater in patients with higher risk
scores; for example, applying the overall proportional
risk reduction (20%) with LCZ696 (compared with
enalapril) in PARADIGM-HF would lead to 6 fewer
patients per 100 treated for 2 years experiencing
events with risk scores of 26 to 40 points (compared
with 2 in the category with 4 to 15 points).
As described in “Methods,” further analyses were
conducted to assess for the misclassiﬁcation of HF
duration. The ﬁndings were consistent with the main
analyses (Online Tables 1 and 2, Online Figures 1 and 2).
Two further sensitivity analyses were conducted,
one according to history of AF and the other by region
(Europe and North America vs. the rest of the world).
Generally, patients with AF had higher absolute rates
CENTRAL ILLUSTRATION Effect of Angiotensin Receptor Neprilysin Inhibitor on Clinical Outcomes:
The MAGGIC Risk Score Category
Simpson, J. et al. J Am Coll Cardiol. 2015; 66(19):2059–71.
After categorizing patients into quintiles on the basis of the Meta-Analysis Global Group in Chronic Heart Failure risk score, the rate per 100 patient-years
of follow-up was determined for (A) the primary composite endpoint, (B) cardiovascular (CV) death, (C) heart failure (HF) hospitalization, and (D) all-cause
mortality according to baseline risk category and randomized treatment. The incidence of all endpoints increased incrementally with increasing risk
score. The effect of LCZ696 compared with enalapril was consistent across the range of risk scores examined as a categorical variable for all endpoints.
MAGGIC ¼ Meta-Analysis Global Group in Chronic Heart Failure.
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TABLE 3 Occurrence
Hypotension
Symptomatic hypote
Symptomatic hypote
Leading to discontin
Renal impairment
Serum creatinine $2
Serum creatinine $3
Leading to discontin
Hyperkalemia
Serum potassium >5
Serum potassium >6
Leading to discontin
Cough
Any cough
Leading to discontin
Angioedema
No treatment/antihis
Catecholamines/cort
Hospitalized/no airw
Any adverse event lead
Values are n (%).
MAGGIC ¼ Meta-Analysi
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2066of the primary composite endpoint, its components,
and all-cause death. However, event rates increased
with increasing risk score in each rhythm subgroup.
Moreover, the beneﬁt of LCZ696 over enalapril was
consistent across risk categories in both rhythm sub-
groups (Online Tables 3 to 6).
Regionally, the rate of death tended to be lower
and that of HF hospitalization higher in Europe and
North America compared with the rest of the world,
but the rate of the primary composite outcome did
not vary markedly between regions. Event rates
increased with increasing risk score in each region,
and the beneﬁt of LCZ696 over enalapril was con-
sistent across risk categories in both regions
(Online Tables 7 to 10).
ADVERSE EVENTS. Among pre-speciﬁed safety out-
comes in PARADIGM-HF by MAGGIC risk score cate-
gory (Table 3), hyperkalemia (serum potassium
>5.5 mmol/l) was the most common event. In pa-
tients randomized to enalapril (the control group),
hyperkalemia occurred in 13.3% of patients in the
lowest risk score category and 22.2% in the highest
risk score category. The next most common adverse
effect, symptomatic hypotension, occurred in 7.0% of
patients in the lowest and 14.2% in the highest riskof Pre-Speciﬁed Adverse Events by MAGGIC Risk Score Category
4–15 16–18
Enalapril
(n ¼ 859)
LCZ696
(n ¼ 903)
Enalapril
(n ¼ 823)
LCZ696
(n ¼ 814
nsion 60 (7.0) 88 (9.7) 77 (9.4) 83 (10.2
nsion with SBP <90 mm Hg 6 (0.7) 15 (1.7) 10 (1.2) 13 (1.6)
uation 3 (0.3) 6 (0.7) 5 (0.6) 4 (0.5)
.5 mg/dl 11 (1.1) 8 (0.9) 20 (2.4) 17 (2.1)
.0 mg/dl 3 (0.3) 4 (0.4) 13 (1.6) 10 (1.2)
uation 6 (0.7) 3 (0.3) 10 (1.2) 5 (0.6
.5 mmol/l 114 (13.3) 125 (13.8) 135 (16.4) 93 (11.4
.0 mmol/l 29 (3.4) 34 (3.8) 41 (5.0) 27 (3.3)
uation 2 (0.2) 1 (0.1) 2 (0.2) 1 (0.1)
125 (14.6) 79 (8.7) 126 (15.3) 93 (11.4
uation 8 (0.9) 1 (0.1) 7 (0.9) 2 (0.2)
tamines only 2 (0.2) 2 (0.2) 2 (0.2) 5 (0.6
icosteroids without hospitalization 0 (0.0) 2 (0.2) 1 (0.1) 2 (0.2)
ay compromise 1 (0.1) 2 (0.2) 0 (0.0) 0 (0.0
ing to study drug discontinuation 19 (2.2) 9 (1.0) 22 (2.7) 12 (1.5)
s Global Group in Chronic Heart Failure.score category; 1.1% of patients in the lowest risk
score category had renal dysfunction (a serum
creatinine $2.5 mg/dl) compared with 10.5% in the
highest risk score category. All 3 of these adverse
events showed a trend to be more common in higher
risk patients. The frequency of cough did not vary
across risk score categories, and the frequency of
angioedema was too low to analyze. The differential
effect of LCZ696 compared with enalapril (e.g., more
hypotension with LCZ696 than enalapril) was gener-
ally maintained across risk score categories (Table 3).
EMPHASIS-HF RISK SCORE ANALYSES. Overall, 6,112
patients were in NYHA functional class I or II and had
complete data across all 10 variables required for
calculation of the EMPHASIS-HF risk score. The
mean age was 63 years, and 79.6% of participants
were men. Figure 1B shows the distribution of
EMPHASIS-HF risk scores in this subset of patients in
PARADIGM-HF. The median score was 5 points (IQR: 4
to 6 points; range: 0 to 12 points). Table 4 shows the
number and proportion of patients in the different
EMPHASIS-HF risk-score categories analyzed.
The differences between those with lower and
higher EMPHASIS-HF risk scores exactly mirrored
those reported for theMAGGIC risk score. Similar to theRisk Score Category (Points)
19–21 22–25 26–40
)
Enalapril
(n ¼ 865)
LCZ696
(n ¼ 810)
Enalapril
(n ¼ 937)
LCZ696
(n ¼ 905)
Enalapril
(n ¼ 717)
LCZ696
(n ¼ 742)
) 68 (7.9) 117 (14.4) 81 (8.6) 149 (16.5) 102 (14.2) 150 (20.2)
12 (1.4) 24 (3.0) 11 (1.2) 24 (2.7) 20 (2.8) 36 (4.9)
0 (0.0) 6 (0.7) 11 (1.2) 8 (0.9) 10 (1.4) 11 (1.5)
33 (3.8) 21 (2.6) 49 (5.2) 39 (4.3) 75 (10.5) 53 (7.1)
15 (1.7) 11 (1.4) 19 (2.0) 15 (1.7) 33 (4.6) 23 (3.1)
) 8 (0.9) 4 (0.5) 16 (1.7) 10 (1.1) 19 (2.6) 7 (0.9)
) 135 (15.6) 143 (17.7) 182 (19.4) 156 (17.2) 159 (22.2) 154 (20.8)
42 (4.9) 41 (5.1) 59 (6.3) 39 (4.3) 65 (9.1) 40 (5.4)
4 (0.5) 1 (0.1) 1 (0.1) 4 (0.4) 6 (0.8) 4 (0.5)
) 124 (14.3) 100 (12.3) 127 (13.6) 114 (12.6) 98 (13.7) 87 (11.7)
4 (0.5) 1 (0.1) 6 (0.6) 3 (0.3) 5 (0.7) 1 (0.1)
) 0 (0.0) 1 (0.1) 0 (0.0) 2 (0.2) 2 (0.3) 1 (0.1)
3 (0.3) 1 (0.1) 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0)
) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.1)
15 (1.7) 12 (1.5) 34 (3.6) 24 (2.7) 39 (5.4) 21 (2.8)
TABLE 4 EMPHASIS-HF Risk Score: Baseline Characteristics and Treatment
Risk Score Category (Points)
p Value for Trend
0–3
(n ¼ 1,499)
4
(n ¼ 1,314)
5
(n ¼ 1,325)
6
(n ¼ 987)
7–12
(n ¼ 987)
Age, yrs 58.7  11.2 60.7  11.2 63.0  10.8 65.9  10.8 69.9  10.1 <0.0001
Female 450 (30.0) 285 (21.7) 229 (17.3) 158 (16.0) 126 (12.8) <0.0001
Race <0.0001
White 901 (60.1) 776 (59.1) 830 (62.6) 600 (60.8) 611 (61.9)
Black 135 (9.0) 81 (6.2) 65 (4.9) 38 (3.9) 37 (3.7)
Asian 245 (16.3) 282 (21.5) 263 (19.8) 244 (24.7) 258 (26.1)
Other 218 (14.5) 175 (13.3) 167 (12.6) 105 (10.6) 81 (8.2)
Region <0.0001
North America 68 (4.5) 76 (5.8) 106 (8.0) 85 (8.6) 131 (13.3)
Latin America 370 (24.7) 283 (21.5) 272 (20.5) 177 (17.9) 136 (13.8)
Western Europe and other 369 (24.6) 321 (24.4) 342 (25.8) 265 (26.8) 287 (29.1)
Central Europe 442 (29.5) 357 (27.2) 344 (26.0) 221 (22.4) 183 (18.5)
Asia-Paciﬁc 250 (16.7) 2,797 (21.1) 261 (19.7) 239 (24.2) 250 (25.3)
SBP, mm Hg 126.2  16.5 121.2  15.8 118.8  14.8 118.5  14.2 116.7  13.0 <0.0001
DBP, mm Hg 76.5  10.0 73.9  10.1 72.5  9.6 71.8  9.9 69.3  9.4 <0.0001
Heart rate, beats/min 70.0  10.3 71.4  11.6 72.2  12.4 73.0  12.2 73.5  12.5 <0.0001
BMI, kg/m2 29.4  5.34 27.9  5.2 27.7  5.3 27.19  5.4 26.1  4.9 <0.0001
Creatinine, mmol/l 82.1  15.1 90.3  18.9 100.4  23.5 111.4  25.6 121.5  26.1 <0.0001
eGFR, ml/min/1.73 m2 81.0  16.4 74.6  18.9 67.0  20.0 58.9  16.6 51.9  14.4 <0.0001
Hemoglobin, g/l 144.1  13.0 142.4  14.6 140.2  15.6 137.7  16.4 128.9  16.6 <0.0001
BNP, pg/ml 224.1 (139.9–400.2) 234.8 (144.9–406.4) 239.8 (144.7–435.6) 258.5 (158.0–487.2) 291.6 (168.5–552.0) <0.0001
NT-proBNP, pg/ml 1,277 (771–2,373) 1,420 (808–2,684) 1,521 (881–2,981) 1,728 (989–3,460) 2,099 (1,084–4,124) <0.0001
Ischemic etiology 526 (35.1) 681 (51.8) 799 (60.3) 683 (69.2) 812 (82.3) <0.0001
Ejection fraction, % 29.8  6.1 29.0  6.3 29.3  6.3 29.1  6.0 28.9  6.5 0.01
NYHA functional class
I 110 (7.3) 79 (6.0) 77 (5.8) 65 (6.6) 49 (5.0)
II 1,389 (92.7) 1,235 (94.0) 1,248 (94.2) 922 (93.4) 938 (95.0)
KCCQ score 86.3 (71.9–94.8) 87.0 (72.9–95.3) 83.9 (70.8–93.8) 83.3 (69.3–93.8) 81.3 (66.7–91.7) <0.0001
Medical history
Hypertension 992 (66.2) 830 (63.2) 912 (68.8) 705 (71.4) 701 (71.0) <0.0001
Diabetes 192 (12.8) 347 (26.4) 489 (36.9) 443 (44.9) 577 (58.5) <0.0001
Atrial ﬁbrillation 480 (32.0) 358 (27.2) 430 (32.5) 351 (35.6) 364 (36.9) <0.0001
Hospitalization for heart failure 616 (41.1) 769 (58.5) 821 (62.0) 692 (70.1) 781 (79.1) <0.0001
Myocardial infarction 268 (17.9) 473 (36.0) 601 (45.4) 550 (55.7) 684 (69.3) <0.0001
Stroke 88 (5.9) 92 (7.0) 114 (8.6) 70 (7.1) 106 (10.7) 0.001
Coronary artery bypass grafting 87 (5.8) 141 (10.7) 215 (16.2) 215 (21.8) 302 (30.6) <0.0001
Percutaneous coronary intervention 165 (11.0) 266 (20.2) 313 (23.6) 281 (28.5) 328 (33.2) <0.0001
Treatment
Diuretic agent 1,136 (75.8) 1,011 (76.9) 1,031 (77.8) 765 (77.5) 832 (84.3) <0.0001
Digoxin 442 (29.5) 396 (30.1) 384 (29.0) 269 (27.3) 277 (28.1) 0.58
Beta-blocker 1,405 (93.7) 1,238 (94.2) 1,242 (93.7) 915 (92.7) 893 (90.5) 0.0043
Mineralocorticoid receptor antagonist 791 (52.8) 749 (57.0) 751 (56.7) 509 (51.6) 496 (50.3) 0.0016
Oral anticoagulant agent 428 (28.6) 394 (30.0) 428 (32.3) 289 (29.3) 301 (30.5) 0.272
Antiplatelet agent 722 (48.2) 732 (55.7) 766 (57.8) 628 (63.6) 663 (67.2) <0.0001
Lipid-lowering agent 690 (46.0) 704 (53.6) 798 (60.2) 630 (63.8) 716 (72.5) <0.0001
Implantable cardioverter-deﬁbrillator 164 (10.9) 179 (13.6) 206 (15.5) 186 (18.8) 206 (20.9) <0.0001
Cardiac resynchronization therapy 51 (3.4) 84 (6.4) 95 (7.2) 82 (8.3) 110 (11.1) <0.0001
Values are mean  SD, n (%), or median (interquartile range).
EMPHASIS-HF ¼ Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; other abbreviation as in Table 1.
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2067MAGGIC analysis, there was an approximately 2-fold
increase in the rate of all outcomes examined
comparing the highest with the lowest EMPHASIS-HF
risk score category (Table 5). Likewise, the effect ofLCZ696 compared with enalapril was consistent across
the range of risk scores examined as a categorical
(Figure 2) or continuous (Figure 1B) variable, with the
greatest absolute beneﬁt in those at highest risk.
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2068DISCUSSION
This study’s main ﬁndings demonstrate that there
was a broad spectrum of risk among the patients with
HFrEF randomized in PARADIGM-HF and that the
beneﬁts of LCZ696 over enalapril were consistent
across this spectrum of risk.
ANALYSIS BY RISK SCORE. The MAGGIC risk score
was derived from an analysis of 39,372 patients
enrolled in 30 clinical trials and cohort studies and
validated in 51,043 patients in a large Swedish HF
registry (4,8).
In the MAGGIC derivation cohort, the median risk
score was 23 points (range: 0 to 52 points) (4),
whereas in PARDIGM-HF, the median score was 20
points (range: 4 to 40 points). The lower median
score (and range) in PARADIGM-HF reﬂects the
exclusion of patients with a low SBP and/or low eGFR
and the high use of beta-blockers, all prognostic
variables in the MAGGIC risk score. Patients in
CHARM with HFrEF also had a higher median risk
score (26 points; range: 10 to 46 points) than in
PARADIGM-HF because of the lower use of beta-
blockers (55%) and greater proportion of patients in
NYHA functional class III (52.4% vs. w24% in
PARADIGM-HF) (9). In EMPHASIS-HF, in which all
patients were in NYHA functional class II and 87%
were treated with beta-blockers, the median MAGGIC
risk score of 21 points was similar to that in
PARADIGM-HF, although the range of 7 to 38 points
was narrower (1).
Despite the majority of patients in PARADIGM-HF
being in NYHA functional class II at baseline, the
incidence of the primary outcome ranged from 7.6 to
20.6 per 100 patient-years of follow-up in the lowest
(4 to 15 points) and highest (26 to 40 points) quintiles,
respectively, emphasizing the limited relationship
between symptoms and risk of hospitalization and
death. In other words, although most patients in
PARADIGM-HF had “mild” symptoms, many were not
at low risk. There was a similar 2- to 3-fold difference
in risk for cardiovascular and all-cause death, as well
as HF hospitalization, when comparing the highest
and lowest quintiles of score.
The value of a multivariate score, such as MAGGIC,
in discriminating risk is further illustrated by com-
parison with the published univariate subgroups.
Those in the highest quintile of the MAGGIC risk score
were at higher risk than patients in any of the pre-
speciﬁed subgroups of PARADIGM-HF; for instance,
in patients ages 75 years and older, the rate of the
primary outcome was 14.8 per 100 patient-years in
the enalapril group (vs. 20.7 per 100 patient-years in
FIGURE 2 Clinical Outcomes (Expressed as a Rate per 100 Patient-Years of Treatment) by EMPHASIS Risk-Score Quintile
CV death or hospitalization Cardiovascular Death
Hospitalization for heart failure All cause death
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2069the highest risk score quintile) (4). Moreover, the
MAGGIC risk score represents a more comprehensive
measure of risk than any of the individual univariate
measures of risk.
The EMPHASIS-HF risk score was developed for the
primary composite outcome of cardiovascular death
or HF hospitalization using a similar approach to that
used in MAGGIC and validated in a subset of patients
from CHARM (2). However, unlike MAGGIC, hemato-
logic and biochemical variables were available in the
EMPHASIS-HF dataset. Additionally, the EMPHASIS-
HF risk model does not take account of NYHA func-
tional class (as all patients were in NYHA functional
class II) or treatment (as the vast majority of patientswere treated with ACEIs or ARBs and beta-blockers).
The maximum possible score is 12 points (range:
0 to 12 points). The median score (5 points) in
PARADIGM-HF patients in NYHA functional class I or
II was identical to that in EMPHASIS-HF, although the
range was wider in PARADIGM-HF (0 to 12 points;
quartile 1 to quartile 3: 4 to 6 points) than in
EMPHASIS-HF (0 to 11 points; quartile 1 to quartile 3:
3 to 6 points).
The beneﬁt of LCZ696 over enalapril was apparent
across the spectrum of risk, with no evidence of
an interaction between risk score and treatment ef-
fect for the primary composite outcome, cardiovas-
cular death, and all-cause mortality. There was a
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2070statistically signiﬁcant interaction between treatment
effect and score for HF hospitalization. Although the
magnitude of the effect varied, the direction of effect,
i.e., beneﬁt of LCZ696, was consistent. The greatest
absolute beneﬁt of LCZ696 versus enalapril was ob-
tained in patients at highest absolute risk. For
instance, if the overall proportional risk reduction for
treatment with LCZ696 compared with enalapril is
applied to the highest quintile of MAGGIC risk score,
approximately 7 fewer patients per 100 treated for 2
years would experience a ﬁrst occurrence of the pri-
mary composite outcome; in the lowest risk category,
approximately 3 fewer patients would experience this
outcome. For deaths, these numbers would be
approximately 6 versus 2. This indicates that within
the overall PARADIGM-HF population, with mainly
mild symptoms and little functional limitation, there
is a substantial subset not just at high risk but also
with much to gain from angiotensin receptor nepri-
lysin inhibitor therapy over a relatively short period
of time. The number needed to treat in the high-risk
category over 2 years to avoid 1 primary outcome is
15 and to avoid 1 death is 16. Even those in the lowest
risk category have clinically worthwhile beneﬁts: the
number needed to treat over 2 years to avoid 1 pri-
mary outcome among these patients is 33 and to
avoid 1 death is 63.
The beneﬁt of LCZ696 over enalapril was
apparent across the spectrum of risk deﬁned by the
EMPHASIS-HF risk score, and even within this subset
of patients in NYHA functional classes I and II, the
spread of risk for the primary composite outcome in
the enalapril group was from 9.3 events per 100
patient-years (score 0 to 3 points) to 19.0 events per
100 patient-years (score 7 to 12 points). The equivalent
rates for death were 6.50 and 11.52 per 100 patient-
years, respectively. This means that even among
patients with mild symptoms, treating 100 patients
in the highest risk category for 2 years with
LCZ696 instead of enalapril could postpone or prevent
3 or 4 primary outcomes and 2 deaths (applying the
overall proportional risk reduction with LCZ696).
STUDY LIMITATIONS. Although the MAGGIC risk
score was derived from a very large cohort of pa-
tients, the studies included were recruited between
1980 and 2006, and routine blood tests and natri-
uretic peptide concentrations were not available in
the majority. However, although natriuretic peptides
are powerful predictors of outcomes, they are still not
available routinely at many sites and in many coun-
tries. Therefore, alternative means of risk stratiﬁ-
cation on the basis of readily available clinical
information remain valuable. The MAGGIC risk scoreincludes 1 point for a diagnosis of HF of 18 months or
longer. The duration of HF in PARADIGM-HF was
recorded as >1 to 2 years or >2 to 5 years, so for our
main analysis, we assigned 1 point to patients with
diagnoses of HF for 1 year or longer. However, we
conducted a sensitivity analysis using a duration of
HF of $2 years, with consistent ﬁndings.
Limitations inherent to secondary analyses must
also be considered when interpreting these results; in
particular, the analyses were not powered for this
purpose. The MAGGIC score was developed to esti-
mate the risk for all-cause mortality, whereas we have
used this score to stratify patients in relation to risk
for several other outcomes. However, as shown
earlier, the MAGGIC score seemed to discriminate risk
for these other outcomes. Moreover, we used an
alternative score, the EMPHASIS-HF risk score, which
was developed for the composite of cardiovascular
death or HF hospitalization and which was specif-
ically derived in patients with mild symptoms (NYHA
functional class II only). This score does incorporate
routine blood tests (hemoglobin and eGFR). Analysis
of this score gave qualitatively similar ﬁndings to
the MAGGIC score. Many other risk scores exist, each
with strengths and weaknesses (10). Patients enrolled
in the studies included in the MAGGIC meta-analyses
did not require an elevated natriuretic peptide
level, whereas patients enrolled in PARADIGM-HF
did. However, we believe that there were many
“PARADIGM-HF-like” patients among the broad
spectrum of 39,372 patients included in the 30 studies
used in the MAGGIC meta-analysis, and our analyses
show that the MAGGIC score was predictive of out-
comes in PARADIGM-HF patients. Our ﬁndings also
apply only to selected patients with HFrEF able to
tolerate an ACEI or ARB and without marked renal
dysfunction, hypotension, or hyperkalemia.CONCLUSIONS
Although most patients in the overall PARADIGM-HF
population had mild symptoms, many were at high
risk for adverse outcomes and obtained a large abso-
lute beneﬁt from the angiotensin receptor neprilysin
inhibitor LCZ696, compared with enalapril, over
a relatively short period of time. However, even
patients at lower risk beneﬁted from LCZ69.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Patients
with HF may have minimal symptoms and little functional
limitation when optimally treated yet remain at risk for
adverse outcomes, including death. Prognostic variables
such LVEF and comorbidities only weakly correlate with
symptoms and functional capacity.
TRANSLATIONAL OUTLOOK: Additional research is
needed to identify more consistent predictors of out-
comes in patients with HF to inform assessments of the
impact of treatment.
J A C C V O L . 6 6 , N O . 1 9 , 2 0 1 5 Simpson et al.
N O V E M B E R 1 0 , 2 0 1 5 : 2 0 5 9 – 7 1 Effect of ARNI According to the MAGGIC Risk Score
2071RE F E RENCE S1. Zannad F, McMurray JJ, Krum H, et al., for the
EMPHASIS-HF Study Group. Eplerenone in pa-
tients with systolic heart failure and mild symp-
toms. N Engl J Med 2011;364:11–21.
2. Collier TJ, Pocock SJ, McMurray JJ, et al. The
impact of eplerenone at different levels of risk in
patients with systolic heart failure and mild
symptoms: insight from a novel risk score for
prognosis derived from the EMPHASIS-HF trial.
Eur Heart J 2013;34:2823–9.
3. McMurray JV, Packer M, Desai AS, et al., for the
PARADIGM-HF Investigators and Committees.
Angiotensin–neprilysin inhibition versus enalapril
in heart failure. N Engl J Med 2014;371:993–1004.
4. Pocock SJ, Ariti CA, McMurray JJ, et al., for the
Meta-Analysis Global Group in Chronic Heart
Failure. Predicting survival in heart failure: a risk
score based on 39 372 patients from 30 studies.
Eur Heart J 2013;34:1404–13.
5. McMurray JJ, Packer M, Desai AS, et al. Dual
angiotensin receptor and neprilysin inhibition as analternative to angiotensin-converting enzyme inhi-
bition in patients with chronic systolic heart failure:
rationale for and design of the Prospective Com-
parison of ARNI with ACEI to Determine Impact on
Global Mortality and Morbidity in Heart Failure trial
(PARADIGM-HF). Eur J Heart Fail 2013;15:1062–73.
6. McMurray JJ, Packer M, Desai AS, et al., for the
PARADIGM-HF Committees Investigators. Baseline
characteristics and treatment of patients in Pro-
spective Comparison of ARNI with ACEI to Deter-
mine Impact on Global Mortality and Morbidity in
Heart Failure trial (PARADIGM-HF). Eur J Heart
Fail 2014;16:817–25.
7. Packer M, McMurray JJ, Desai AS, et al., for the
PARADIGM-HF Investigators and Coordinators.
Angiotensin receptor neprilysin inhibition
compared with enalapril on the risk of clinical
progression in surviving patients with heart
failure. Circulation 2015;131:54–61.
8. Sartipy U, Dahlström U, Edner M, Lund LH.
Predicting survival in heart failure: validation ofthe MAGGIC heart failure risk score in 51,043
patients from the Swedish heart failure registry.
Eur J Heart Fail 2014;16:173–9.
9. Pfeffer MA, Swedberg K, Granger CB, et al., for
the CHARM Investigators and Committees. Effects
of candesartan on mortality and morbidity in
patients with chronic heart failure: the CHARM-
Overall programme. Lancet 2003;362:759–66.
10. Ferrero P, Iacovoni A, D’Elia E, et al. Prognostic
scores in heart failure—critical appraisal and prac-
tical use. Int J Cardiol 2015;188:1–9.KEY WORDS angiotensin receptor
neprilysin inhibitor, prognostic model,
risk score, survivalAPPENDIX For supplemental tables and
ﬁgures, please see the online version of this
article.
